In all the hoopla over the new FDA funding-and-reform legislation last month, a key provision was eclipsed--the creation of a new research center paid for by drug makers. The Reagan-Udall Foundation is designed to streamline and improve drug development. But as the Associated Press notes, a research collaboration yoking pharma with the FDA creates an entirely new form of regulator-regulatee relationship--one that might get drugs to market more quickly and more cheaply, but even less safely.
The FDA is fast-tracking nominations to the new center's board, with members slated to be named by October 27. Four of the fourteen members are expected to be pharma executives.
- check out the FDA release seeking nominations for the board
- read the AP's take on the foundation
Related Articles:
FDA, Big Pharma collaborate on genetic tests. Report
House overhauls, passes PDUFA. Report
Bickering may stall trial database. Report
PDUFA debate highlights drug safety issues. Report
Read more on: FDA news